Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLife SolutionsBLFS +0.09%73 Price-to-Tangible-Book is 8.22 as of Sep. 12, 2026. GuruFocus rates BLFS with a GF Score™ of 73/100 and a GF Value™ of $30.54 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 700 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 82.43% on this metric.
The historical rank and industry rank for BioLife Solutions's Price-to-Tangible-Book or its related term are showing as below:
BLFS'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.63 Med: 9.13 Max: 16.73
Current: 8.22
During the past 13 years, BioLife Solutions's highest Price to Tangible Book Ratio was 16.73. The lowest was 4.63. And the median was 9.13.
BLFS's Price-to-Tangible-Book is ranked worse than 82.43% of 700
companies
in the Medical Devices & Instruments industry
Industry Median: 2.595
vs BLFS: 8.22
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
BioLife Solutions Price-to-Tangible-Book Related Terms
BioLife Solutions Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLFS vs LMAT, KMTS, AZTA: Price-to-Tangible-Book Comparison
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
BioLife Solutions (BLFS) has a Price-to-Tangible-Book of 8.22 as of Sep. 12, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on BioLife Solutions and its competitors. According to the industry distribution chart, BioLife Solutions ranks #577 out of 700 companies in the Medical Devices & Instruments industry, placing it in the top 82.4%.
Is BioLife Solutions' Price-to-Tangible-Book too high?
BioLife Solutions' current Price-to-Tangible-Book is 8.22. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.60. BioLife Solutions' value of 8.22 is 216.8% above this industry median. Based on the distribution chart, BioLife Solutions ranks #577 out of 700 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BioLife Solutions has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Price-to-Tangible-Book compare to LMAT and KMTS?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #577 out of 700 companies for Price-to-Tangible-Book. This places BioLife Solutions in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.60. BioLife Solutions' value of 8.22 is 216.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.60, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Price-to-Tangible-Book of 8.22 is 216.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Price-to-Tangible-Book is 8.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Modestly Overvalued. The stock's GF Value™ is $30.54, compared to a current price of $34.95 — trading 14.4% above its estimated fair value. The current Price-to-Tangible-Book is 8.22 and 216.8% above the Medical Devices & Instruments industry median of 2.60. BioLife Solutions' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Price-to-Tangible-Book is 8.22 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of $34.95 is trading 14.4% above its estimated GF Value™ of $30.54.
GuruFocus considers BioLife Solutions to be Modestly Overvalued.
Key valuation signals for BLFS:
Price-to-Tangible-Book: 8.22
GF Value™: $30.54 vs. price of $34.95 (14.4% above fair value)
Industry Position: 216.8% above the Medical Devices & Instruments median (#577 of 700)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
73GF Score
Get the complete analysis for BLFS
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
